Typical Dosing Progression Weeks 14: The loading or initiation phase
GLP-1RAs should therefore be used cautiously for the HFrEF phenotype, with decisions driven primarily by coexisting ASCVD, obesity, or HFpEF rather than by HFrEF itself
For patients with clinical obesity, type 2 diabetes, or cardiovascular risk that requires rapid medical intervention, they remain one of the most effective tools available
Yes, electrolytes help reduce GLP-1 nausea by addressing dehydration, which amplifies nausea severity
Antioxidants including glutathione provide additional cardioprotective effects
Given that, in the Italian specialist care setting, patients with T2D who are not on insulin are seen every 69 months, we assume that most patients were recommended to self-titrate to 7 mg after one month of therapy with the 3 mg dose, but that the titration to 14 mg was suggested after the follow-up visit